AbSci, a Vancouver, Wash.-based protein printing company, closed a $10.4M Series D financing.
The round was led by KBI Biopharma and JSR Life Sciences with participation from existing investors Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Columbia Ventures Corporation.
The financing also includes $5M in term debt. The company intends to use the funds for expansion of its facilities and team in order to meet commercial demand for its technology.
Led by Sean McClain, Founder and CEO, AbSci has developed Protein Printing™ technology which combines E. coli SoluPro® with a synthetic biology platform for generation of high-diversity strain libraries and high-throughput screening assays to deliver titers of complex biotherapeutic proteins with high product quality.
Its patented SoluPro™ expression platform rapidly produces complex proteins, ranging from mAbs, Fabs, enzymes, hormones and peptides, to emerging novel classes of biotherapeutics.
In addition, AbSci and KBI Biopharma have entered into an exclusive co-marketing agreement to jointly market and promote each other’s technologies, products, and services. Under the agreement, KBI Biopharma, a biopharmaceutical CDMO providing fully integrated biopharmaceutical development and manufacturing services, has the exclusive right to market AbSci’s Protein Printing™ technology worldwide and is AbSci’s preferred CDMO for industrial scale-up of biologics developed using AbSci technology.